New York, January 12, 2026, 15:41 ET — Regular session
Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.
The message is crucial as Arcutis hits a stage where investors demand more than just rapid script growth — they want evidence it can scale without another cash drain. One marketed franchise can sustain a company, until it can’t.
It also locks in a timeline. In biotech, these calendars drive stock moves: trial readouts, filing deadlines, FDA review periods. Traders often position themselves ahead of these dates, then bail quickly if there’s a delay.
Arcutis projects 2026 net product sales between $455 million and $470 million and plans to grow its dermatology sales team by roughly 20%. CEO Frank Watanabe emphasized their goal to “accelerate the conversion from topical corticosteroids” as they push ZORYVE for psoriasis, atopic dermatitis, and seborrheic dermatitis. The company expects topline data from the INTEGUMENT-INFANT study in Q1 and has set an FDA target action date of June 29, 2026, for a pediatric plaque psoriasis label expansion. They also plan to kick off a Phase 1 trial of ARQ-234 in early 2026. GlobeNewswire
Net product sales refers to drug industry revenue after factoring in rebates, returns, and other discounts. An sNDA, or supplemental new drug application, seeks to broaden an already approved label. The PDUFA date marks the FDA’s user-fee deadline for deciding on that approval.
Arcutis posted $99.2 million in net product revenue from ZORYVE in its most recent quarter, wrapping Sept. 30 with a $7.4 million profit. The SEC filing revealed the company held $191.4 million in cash, cash equivalents, and marketable securities.
On Monday, Arcutis underperformed the wider biotech sector, while the SPDR S&P Biotech ETF slipped roughly 0.8%.
The stock has swung from a 52-week low of $11.13 up to a peak of $31.77, per the company’s investor site.
The company is pushing to expand ZORYVE’s reach into more challenging areas like vitiligo, where the market for branded, non-steroid topicals is already packed. Incyte’s Opzelura, a topical JAK inhibitor, holds U.S. approval for both atopic dermatitis and nonsegmental vitiligo, according to FDA labeling.
But the sales range represents a goal, not a guaranteed minimum, and the coming year has plenty of risks — from payer access issues and competition to the complexity of juggling multiple studies simultaneously. Arcutis also warns that ZORYVE is contraindicated for patients with moderate to severe liver impairment.
Investors are focused on whether demand early in 2026 stays strong as Arcutis ramps up spending on sales and pushes to expand its user base. The key date coming up is the FDA’s June 29 deadline for the pediatric plaque psoriasis application, with infant-study results due in the first quarter just before that.
